Lucia Quaglietta1, Massimo Martinelli2, Annamaria Staiano3. 1. Santobono-Pausilipon Children's Hospital, Naples, Italy. 2. Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Via S. Pansini, 5, 80131, Naples, Italy. 3. Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II", Via S. Pansini, 5, 80131, Naples, Italy. staiano@unina.it.
Abstract
PURPOSE OF REVIEW: Despite its recognized efficacy and tolerability profile, during the last decade a rise of adverse events following ibuprofen administration in children has been reported, including a possible role in worsening the clinical course of infections. Our aim was to critically evaluate the safety of ibuprofen during the course of pediatric infectious disease in order to promote its appropriate use in children. RECENT FINDINGS: Ibuprofen is associated with severe necrotizing soft tissue infections (NSTI) during chickenpox course. Pre-hospital use of ibuprofen seems to increase the risk of complicated pneumonia in children. Conflicting data have been published in septic children, while ibuprofen in the setting of Cystic Fibrosis (CF) exacerbations is safe and efficacious. No data is yet available for ibuprofen use during COVID-19 course. Ibuprofen should not be recommended for chickenpox management. Due to possible higher risks of complicated pneumonia, we suggest caution on its use in children with respiratory symptoms. While it remains unclear whether ibuprofen may have harmful effects during systemic bacterial infection, its administration is recommended in CF course. Despite the lack of data, it is seems cautious to prefer the use of paracetamol during COVID-19 acute respiratory distress syndrome in children.
PURPOSE OF REVIEW: Despite its recognized efficacy and tolerability profile, during the last decade a rise of adverse events following ibuprofen administration in children has been reported, including a possible role in worsening the clinical course of infections. Our aim was to critically evaluate the safety of ibuprofen during the course of pediatric infectious disease in order to promote its appropriate use in children. RECENT FINDINGS:Ibuprofen is associated with severe necrotizing soft tissue infections (NSTI) during chickenpox course. Pre-hospital use of ibuprofen seems to increase the risk of complicated pneumonia in children. Conflicting data have been published in septic children, while ibuprofen in the setting of Cystic Fibrosis (CF) exacerbations is safe and efficacious. No data is yet available for ibuprofen use during COVID-19 course. Ibuprofen should not be recommended for chickenpox management. Due to possible higher risks of complicated pneumonia, we suggest caution on its use in children with respiratory symptoms. While it remains unclear whether ibuprofenmay have harmful effects during systemic bacterial infection, its administration is recommended in CF course. Despite the lack of data, it is seems cautious to prefer the use of paracetamol during COVID-19acute respiratory distress syndrome in children.
Authors: Sabrina Cardile; Massimo Martinelli; Arrigo Barabino; Paolo Gandullia; Salvatore Oliva; Giovanni Di Nardo; Luigi Dall'Oglio; Francesca Rea; Gian Luigi de'Angelis; Barbara Bizzarri; Graziella Guariso; Enzo Masci; Annamaria Staiano; Erasmo Miele; Claudio Romano Journal: World J Gastroenterol Date: 2016-02-07 Impact factor: 5.742
Authors: Elena Chiappini; Antonio Vitale; Raffaele Badolato; Paolo Becherucci; Domenico Careddu; Antonio Di Mauro; Mattia Doria; Annamaria Staiano Journal: Front Pediatr Date: 2022-04-26 Impact factor: 3.418
Authors: Elisabetta Gatti; Marta Piotto; Mara Lelii; Mariacarola Pensabene; Barbara Madini; Lucia Cerrato; Vittoria Hassan; Stefano Aliberti; Samantha Bosis; Paola Marchisio; Maria Francesca Patria Journal: Front Pediatr Date: 2022-03-07 Impact factor: 3.418